<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684474</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00090805</org_study_id>
    <nct_id>NCT02684474</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol Using HBOC-201</brief_title>
  <official_title>Expanded Access Protocol Using HBOC-201 to Treat Patients With Life Threatening Anemia, for Whom Blood is Not an Option</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to provide treatment with HBOC-201 to patients with&#xD;
      life-threatening anemia for whom allogeneic blood transfusion is not an option. HBOC 201&#xD;
      [hemoglobin glutamer - 250 (bovine)] has been previously studied as an alternative to blood&#xD;
      transfusions in severely anemic patients needing a way to enhance tissue oxygenation.&#xD;
      HBOC-201 is purified, cross-linked and polymerized acellular bovine hemoglobin in a modified&#xD;
      lactated Ringer's solution, and does not require blood compatibility.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Anemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBOC-201</intervention_name>
    <description>Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.</description>
    <other_name>Hemopure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients ≥ 18 years of age&#xD;
&#xD;
          2. Critically ill patients with hemoglobin ≤ 6 g/dL (or 7-8 g/dL with significant active&#xD;
             bleeding), and physiologic evidence of critical ischemia, for example: elevated&#xD;
             troponins, altered mental status, acute renal failure, lactic acidosis or evidence of&#xD;
             central nervous system acute deficits&#xD;
&#xD;
          3. Patients or their Legally Authorized Representative who are able and willing to&#xD;
             provide informed consent&#xD;
&#xD;
          4. Blood is not an option due to:&#xD;
&#xD;
               -  refusal of transfusion&#xD;
&#xD;
               -  lack of compatible red blood cells&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with known hypersensitivity or allergy to beef products&#xD;
&#xD;
          2. Patients with pre-existing uncontrolled hypertension, heart failure, renal failure,&#xD;
             circulatory hypervolemia or systemic mastocytosis*&#xD;
&#xD;
          3. Patients who are eligible for blood transfusions&#xD;
&#xD;
          4. Patients who are &gt; 80 years old*&#xD;
&#xD;
               -  on a case by case and quality of life determination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Steven M Frank, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven M Frank, MD</last_name>
    <phone>410-955-8465</phone>
    <email>sfrank3@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda MS Resar, MD</last_name>
    <phone>410-614-0712</phone>
    <email>lresar@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Frank SM, Wick EC, Dezern AE, Ness PM, Wasey JO, Pippa AC, Dackiw E, Resar LM. Risk-adjusted clinical outcomes in patients enrolled in a bloodless program. Transfusion. 2014 Oct;54(10 Pt 2):2668-77. doi: 10.1111/trf.12752. Epub 2014 Jun 18.</citation>
    <PMID>24942198</PMID>
  </reference>
  <reference>
    <citation>Resar LM, Frank SM. Bloodless medicine: what to do when you can't transfuse. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):553-8. doi: 10.1182/asheducation-2014.1.553. Epub 2014 Nov 18. Review.</citation>
    <PMID>25696910</PMID>
  </reference>
  <reference>
    <citation>Chaturvedi S, Koo M, Dackiw L, Koo G, Frank SM, Resar LMS. Preoperative treatment of anemia and outcomes in surgical Jehovah's Witness patients. Am J Hematol. 2019 Feb;94(2):E55-E58. doi: 10.1002/ajh.25359. Epub 2018 Dec 18.</citation>
    <PMID>30474135</PMID>
  </reference>
  <reference>
    <citation>Resar LM, Wick EC, Almasri TN, Dackiw EA, Ness PM, Frank SM. Bloodless medicine: current strategies and emerging treatment paradigms. Transfusion. 2016 Oct;56(10):2637-2647. doi: 10.1111/trf.13736. Epub 2016 Jul 29. Review.</citation>
    <PMID>27473810</PMID>
  </reference>
  <reference>
    <citation>Visagie M, Pearson KR, Purvis TE, Gehrie EA, Resar LMS, Frank SM. Greater anemia tolerance among hospitalized females compared to males. Transfusion. 2019 Aug;59(8):2551-2558. doi: 10.1111/trf.15338. Epub 2019 May 7.</citation>
    <PMID>31063596</PMID>
  </reference>
  <reference>
    <citation>Frank SM, Chaturvedi S, Goel R, Resar LMS. Approaches to Bloodless Surgery for Oncology Patients. Hematol Oncol Clin North Am. 2019 Oct;33(5):857-871. doi: 10.1016/j.hoc.2019.05.009. Epub 2019 Jul 31. Review.</citation>
    <PMID>31466609</PMID>
  </reference>
  <reference>
    <citation>Guinn NR, Resar LMS, Frank SM. Perioperative Management of Patients for Whom Transfusion Is Not an Option. Anesthesiology. 2021 Jun 1;134(6):939-948. doi: 10.1097/ALN.0000000000003763. Review.</citation>
    <PMID>33857295</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HBOC 201</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

